Effect of low-dose theophylline on airway inflammation in COPD

Motoko Kobayashi, Yasuyuki Nasuhara, Tomoko Betsuyaku, Eiji Shibuya, Yoshinori Tanino, Mishie Tanino, Kei Takamura, Katsura Nagai, Takeshi Hosokawa, Masaharu Nishimura

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Objective: Recent studies have shown that theophylline may exert anti-inflammatory effects on neutrophils. We undertook to assess the effect of theophylline on airway inflammation in COPD. Methodology: We performed a 4-week randomized double-blind, placebo-controlled study in 11 theophylline-naive patients with mild to moderate COPD. After a 1-week run-in period, six subjects were administered 400 mg/day theophylline (Theodur; Nikken Chemicals Co. Ltd, Tokyo, Japan) for 4 weeks, while five subjects were administered a placebo. Induced sputum was obtained before and after the run-in period and then after 2 and 4 weeks of treatment. Cell differential count and levels of interleukin-8, matrix metalloproteinase-9, neutrophil elastase (NE), myeloperoxidase (MPO), α1-antitrypsin (αs1-AT), leukotriene B 4 and tissue inhibitor of metalloproteinases-1 (TIMP-1) were assessed. Results: No variable was significantly different during the run-in period or with placebo treatment. In contrast, theophylline treatment significantly decreased NE and MPO levels at 4 weeks, although the cell differential count did not change appreciably as a result of treatment. Conclusion: These results suggest that 4 weeks of theophylline treatment attenuates neutrophil-associated inflammation in the airways of mild to moderate COPD patients. However, the clinical benefits remain to be determined.

Original languageEnglish
Pages (from-to)249-254
Number of pages6
JournalRespirology
Volume9
Issue number2
DOIs
Publication statusPublished - 2004 Jun
Externally publishedYes

Fingerprint

Theophylline
Chronic Obstructive Pulmonary Disease
Inflammation
Leukocyte Elastase
Placebos
Peroxidase
Neutrophils
Cell Count
Therapeutics
Tissue Inhibitor of Metalloproteinase-1
Leukotriene B4
Tokyo
Matrix Metalloproteinase 9
Sputum
Interleukin-8
Japan
Anti-Inflammatory Agents

Keywords

  • Airway inflammation
  • COPD
  • Induced sputum
  • Neutrophils
  • Theophylline

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Kobayashi, M., Nasuhara, Y., Betsuyaku, T., Shibuya, E., Tanino, Y., Tanino, M., ... Nishimura, M. (2004). Effect of low-dose theophylline on airway inflammation in COPD. Respirology, 9(2), 249-254. https://doi.org/10.1111/j.1440-1843.2004.00573.x

Effect of low-dose theophylline on airway inflammation in COPD. / Kobayashi, Motoko; Nasuhara, Yasuyuki; Betsuyaku, Tomoko; Shibuya, Eiji; Tanino, Yoshinori; Tanino, Mishie; Takamura, Kei; Nagai, Katsura; Hosokawa, Takeshi; Nishimura, Masaharu.

In: Respirology, Vol. 9, No. 2, 06.2004, p. 249-254.

Research output: Contribution to journalArticle

Kobayashi, M, Nasuhara, Y, Betsuyaku, T, Shibuya, E, Tanino, Y, Tanino, M, Takamura, K, Nagai, K, Hosokawa, T & Nishimura, M 2004, 'Effect of low-dose theophylline on airway inflammation in COPD', Respirology, vol. 9, no. 2, pp. 249-254. https://doi.org/10.1111/j.1440-1843.2004.00573.x
Kobayashi M, Nasuhara Y, Betsuyaku T, Shibuya E, Tanino Y, Tanino M et al. Effect of low-dose theophylline on airway inflammation in COPD. Respirology. 2004 Jun;9(2):249-254. https://doi.org/10.1111/j.1440-1843.2004.00573.x
Kobayashi, Motoko ; Nasuhara, Yasuyuki ; Betsuyaku, Tomoko ; Shibuya, Eiji ; Tanino, Yoshinori ; Tanino, Mishie ; Takamura, Kei ; Nagai, Katsura ; Hosokawa, Takeshi ; Nishimura, Masaharu. / Effect of low-dose theophylline on airway inflammation in COPD. In: Respirology. 2004 ; Vol. 9, No. 2. pp. 249-254.
@article{bf5de0f4545f4ad683f203bedd7f6424,
title = "Effect of low-dose theophylline on airway inflammation in COPD",
abstract = "Objective: Recent studies have shown that theophylline may exert anti-inflammatory effects on neutrophils. We undertook to assess the effect of theophylline on airway inflammation in COPD. Methodology: We performed a 4-week randomized double-blind, placebo-controlled study in 11 theophylline-naive patients with mild to moderate COPD. After a 1-week run-in period, six subjects were administered 400 mg/day theophylline (Theodur; Nikken Chemicals Co. Ltd, Tokyo, Japan) for 4 weeks, while five subjects were administered a placebo. Induced sputum was obtained before and after the run-in period and then after 2 and 4 weeks of treatment. Cell differential count and levels of interleukin-8, matrix metalloproteinase-9, neutrophil elastase (NE), myeloperoxidase (MPO), α1-antitrypsin (αs1-AT), leukotriene B 4 and tissue inhibitor of metalloproteinases-1 (TIMP-1) were assessed. Results: No variable was significantly different during the run-in period or with placebo treatment. In contrast, theophylline treatment significantly decreased NE and MPO levels at 4 weeks, although the cell differential count did not change appreciably as a result of treatment. Conclusion: These results suggest that 4 weeks of theophylline treatment attenuates neutrophil-associated inflammation in the airways of mild to moderate COPD patients. However, the clinical benefits remain to be determined.",
keywords = "Airway inflammation, COPD, Induced sputum, Neutrophils, Theophylline",
author = "Motoko Kobayashi and Yasuyuki Nasuhara and Tomoko Betsuyaku and Eiji Shibuya and Yoshinori Tanino and Mishie Tanino and Kei Takamura and Katsura Nagai and Takeshi Hosokawa and Masaharu Nishimura",
year = "2004",
month = "6",
doi = "10.1111/j.1440-1843.2004.00573.x",
language = "English",
volume = "9",
pages = "249--254",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Effect of low-dose theophylline on airway inflammation in COPD

AU - Kobayashi, Motoko

AU - Nasuhara, Yasuyuki

AU - Betsuyaku, Tomoko

AU - Shibuya, Eiji

AU - Tanino, Yoshinori

AU - Tanino, Mishie

AU - Takamura, Kei

AU - Nagai, Katsura

AU - Hosokawa, Takeshi

AU - Nishimura, Masaharu

PY - 2004/6

Y1 - 2004/6

N2 - Objective: Recent studies have shown that theophylline may exert anti-inflammatory effects on neutrophils. We undertook to assess the effect of theophylline on airway inflammation in COPD. Methodology: We performed a 4-week randomized double-blind, placebo-controlled study in 11 theophylline-naive patients with mild to moderate COPD. After a 1-week run-in period, six subjects were administered 400 mg/day theophylline (Theodur; Nikken Chemicals Co. Ltd, Tokyo, Japan) for 4 weeks, while five subjects were administered a placebo. Induced sputum was obtained before and after the run-in period and then after 2 and 4 weeks of treatment. Cell differential count and levels of interleukin-8, matrix metalloproteinase-9, neutrophil elastase (NE), myeloperoxidase (MPO), α1-antitrypsin (αs1-AT), leukotriene B 4 and tissue inhibitor of metalloproteinases-1 (TIMP-1) were assessed. Results: No variable was significantly different during the run-in period or with placebo treatment. In contrast, theophylline treatment significantly decreased NE and MPO levels at 4 weeks, although the cell differential count did not change appreciably as a result of treatment. Conclusion: These results suggest that 4 weeks of theophylline treatment attenuates neutrophil-associated inflammation in the airways of mild to moderate COPD patients. However, the clinical benefits remain to be determined.

AB - Objective: Recent studies have shown that theophylline may exert anti-inflammatory effects on neutrophils. We undertook to assess the effect of theophylline on airway inflammation in COPD. Methodology: We performed a 4-week randomized double-blind, placebo-controlled study in 11 theophylline-naive patients with mild to moderate COPD. After a 1-week run-in period, six subjects were administered 400 mg/day theophylline (Theodur; Nikken Chemicals Co. Ltd, Tokyo, Japan) for 4 weeks, while five subjects were administered a placebo. Induced sputum was obtained before and after the run-in period and then after 2 and 4 weeks of treatment. Cell differential count and levels of interleukin-8, matrix metalloproteinase-9, neutrophil elastase (NE), myeloperoxidase (MPO), α1-antitrypsin (αs1-AT), leukotriene B 4 and tissue inhibitor of metalloproteinases-1 (TIMP-1) were assessed. Results: No variable was significantly different during the run-in period or with placebo treatment. In contrast, theophylline treatment significantly decreased NE and MPO levels at 4 weeks, although the cell differential count did not change appreciably as a result of treatment. Conclusion: These results suggest that 4 weeks of theophylline treatment attenuates neutrophil-associated inflammation in the airways of mild to moderate COPD patients. However, the clinical benefits remain to be determined.

KW - Airway inflammation

KW - COPD

KW - Induced sputum

KW - Neutrophils

KW - Theophylline

UR - http://www.scopus.com/inward/record.url?scp=3142744558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142744558&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1843.2004.00573.x

DO - 10.1111/j.1440-1843.2004.00573.x

M3 - Article

C2 - 15182277

AN - SCOPUS:3142744558

VL - 9

SP - 249

EP - 254

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 2

ER -